ArticleThe Lancet regional health. Europe2025
Cardiovascular safety of biologic therapies in patients with severe asthma: a nationwide cohort study in Belgium.
Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A Brief History of COPD: As Told by Some of Its Senior Scientists and Clinicians.Journal of clinical medicine · 2026Review
- Kounis Syndrome Features in Special Populations.Medical sciences (Basel, Switzerland) · 2026Review
- Optimizing COPD Care in Belgium: A Multidisciplinary Expert Consensus on Cardiopulmonary Risk Management.International journal of chronic obstructive pulmonary disease · 2026Article
- From FEVJournal of asthma and allergy · 2026Review
- The roles, mechanisms, and therapeutic implications of glucocorticoids in glucose and lipid metabolism.Military Medical Research · 2026Review
- Real-life impact of anti-IL5 therapy on exacerbation types in patients with obstructive lung disease.BMJ open respiratory research · 2025Article
- Optimizing control of severe asthma contributes to cardiovascular prevention.The Lancet regional health. Europe · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In last decades, biologic therapies have been approved for severe allergic and/or eosinophilic asthma. Limited studies have investigated the effect of biologics on (acute) cardiovascular events, which have reported conflicting results. We aimed to investigate the potential cardiovascular risk of anti-immunoglobulin(Ig)-E (omalizumab) and anti-interleukin(IL)-5/IL5 receptor (IL5R) therapies (mepolizumab and benralizumab) in patients with severe asthma compared with non-biologic users. Methods: Adult asthma patients eligible for biologics were identified in Belgian nationwide data between 2017 and 2022. Inverse probability of treatment weighted Cox regression was used to investigate cardiovascular outcomes and all-cause mortality, while controlling for age, sex, obesity, smoking, comorbidities, comedication, exacerbations, and frailty. Findings: This cohort study consisted of 171,865 patients (mean age 64 years; 55% females) including 1826 (1.1%) anti-IgE users and 2398 (1.4%) anti-IL5/IL5R users. Anti-IgE exposure was associated with a significantly lower risk of mortality (aHR 0.48, 95% CI 0.40-0.58), congestive heart failure (aHR 0.79, 95% CI 0.65-0.95), peripheral artery disease (aHR 0.66, 95% CI 0.51-0.86), and stroke (aHR 0.54, 95% CI 0.36-0.81). Anti-IL5/IL5R use was associated with a significantly lower risk of mortality (aHR 0.35, 95% CI 0.29-0.42), congestive heart failure (aHR 0.63, 95% CI 0.52-0.76), arrythmia (aHR 0.78, 95% CI 0.68-0.90), and peripheral artery disease (aHR 0.69, 95% CI 0.54-0.87) compared with non-biologic users. No significant differences in the risk of myocardial infarction and pulmonary embolism were observed. Interpretation: In this nationwide observational study, biologic therapies for patients with severe asthma were associated with a significantly lower risk of all-cause mortality and specific cardiovascular diseases compared with non-biologic users. Funding: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.